MX2023001570A - Composiciones y métodos para tratar o prevenir una enfermedad asociada a la infección por betacoronavirus. - Google Patents

Composiciones y métodos para tratar o prevenir una enfermedad asociada a la infección por betacoronavirus.

Info

Publication number
MX2023001570A
MX2023001570A MX2023001570A MX2023001570A MX2023001570A MX 2023001570 A MX2023001570 A MX 2023001570A MX 2023001570 A MX2023001570 A MX 2023001570A MX 2023001570 A MX2023001570 A MX 2023001570A MX 2023001570 A MX2023001570 A MX 2023001570A
Authority
MX
Mexico
Prior art keywords
compositions
methods
coronavirus infection
treating
beta
Prior art date
Application number
MX2023001570A
Other languages
English (en)
Spanish (es)
Inventor
Jacqueline M Iversen
Thomas A Dahl
Original Assignee
Sen Jam Pharmaceutical Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sen Jam Pharmaceutical Llc filed Critical Sen Jam Pharmaceutical Llc
Publication of MX2023001570A publication Critical patent/MX2023001570A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023001570A 2020-08-06 2021-08-06 Composiciones y métodos para tratar o prevenir una enfermedad asociada a la infección por betacoronavirus. MX2023001570A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063062138P 2020-08-06 2020-08-06
PCT/US2021/044897 WO2022032069A1 (en) 2020-08-06 2021-08-06 Compositions and methods for treating or preventing disease associated with beta coronavirus infection

Publications (1)

Publication Number Publication Date
MX2023001570A true MX2023001570A (es) 2023-05-03

Family

ID=80117684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001570A MX2023001570A (es) 2020-08-06 2021-08-06 Composiciones y métodos para tratar o prevenir una enfermedad asociada a la infección por betacoronavirus.

Country Status (11)

Country Link
US (1) US20240033259A1 (cg-RX-API-DMAC7.html)
EP (1) EP4192457B1 (cg-RX-API-DMAC7.html)
JP (1) JP7882832B6 (cg-RX-API-DMAC7.html)
KR (1) KR20230048517A (cg-RX-API-DMAC7.html)
CN (1) CN116322662A (cg-RX-API-DMAC7.html)
AU (1) AU2021321535A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188387A1 (cg-RX-API-DMAC7.html)
ES (1) ES3069166T3 (cg-RX-API-DMAC7.html)
IL (1) IL300406A (cg-RX-API-DMAC7.html)
MX (1) MX2023001570A (cg-RX-API-DMAC7.html)
WO (1) WO2022032069A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046201A1 (en) 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION
CN116178373B (zh) * 2022-12-06 2024-06-18 南方科技大学 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018232260A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and compositions to inhibit symptoms associated with viral upper respiratory tract infections
WO2019046201A1 (en) * 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION

Also Published As

Publication number Publication date
JP7882832B6 (ja) 2026-07-31
JP7882832B2 (ja) 2026-06-30
US20240033259A1 (en) 2024-02-01
CA3188387A1 (en) 2022-02-10
EP4192457A4 (en) 2024-09-18
IL300406A (en) 2023-04-01
EP4192457C0 (en) 2026-03-25
JP2023537369A (ja) 2023-08-31
CN116322662A (zh) 2023-06-23
WO2022032069A1 (en) 2022-02-10
EP4192457A1 (en) 2023-06-14
KR20230048517A (ko) 2023-04-11
AU2021321535A1 (en) 2023-03-23
ES3069166T3 (en) 2026-06-04
EP4192457B1 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
CL2023001476A1 (es) Nuevos agentes antivirales derivados de la espiropirrolidina
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
EP2331095A4 (en) CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
EA201591610A1 (ru) Ингибиторы кинуренинового пути
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
JP2016518387A5 (cg-RX-API-DMAC7.html)
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
MX2009008051A (es) Regimen posologico para inhibidores de comt.
Gómez‐Ramírez et al. Short‐term perioperative iron in major orthopedic surgery: state of the art
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112014003981A2 (pt) compostos de pirimido-piridazinona e seu uso
Ke et al. Curcumin-activated autophagy plays a negative role in its anti-osteoclastogenic effect
Tesarik Melatonin attenuates growth factor receptor signaling required for SARS-CoV-2 replication
CY1111783T1 (el) Θεραπεια συνδυασμου διαταραχων κατωτερης ουροποιητικης οδου με 2 προσδεματα και μη στεροειδες αντιφλεγμονωδες φαρμακο
BRPI0923373B8 (pt) composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
BR112023023534A2 (pt) Composição farmacêutica para uso no tratamento de infarto cererbral
BR112022008095A2 (pt) Métodos e composições para o tratamento da síndrome de rett
MX2012002161A (es) El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer.
ECSP10010054A (es) Composiciones farmacéuticas que comprenden la combinación de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa útiles para el control y tratamiento de la gota, artritis gotosa y enfermedades relacionadas
WO2023166492A3 (en) Dual inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy
MX2025010182A (es) Métodos para el tratamiento de las infecciones por gripe